Novavax (FRA:NVV1) Cyclically Adjusted Book per Share: €-2.51 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NVV1 Novavax Inc FRA:NVV1
49 GF Score
Price €8.70
GF Value €2.73
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novavax Cyclically Adjusted Book per Share?

Novavax FRA:NVV1 +2.59% 49 Cyclically Adjusted Book per Share is €-2.51 as of Jun. 2026. GuruFocus rates FRA:NVV1 with a GF Score™ of 49/100 and a GF Value™ of €2.73 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Novavax's adjusted book value per share for the three months ended in Jun. 2026 was €-1.004. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €-2.51 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Novavax was 8.10% per year. The lowest was -41.40% per year. And the median was -5.10% per year.

As of today (2026-09-02), Novavax's current stock price is €8.70. Novavax's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €-2.51. Novavax's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novavax was 35.13. The lowest was 0.39. And the median was 2.51.


Novavax  (FRA:NVV1) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novavax was 35.13. The lowest was 0.39. And the median was 2.51.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Novavax Cyclically Adjusted Book per Share Related Terms


Novavax Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Novavax's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Cyclically Adjusted Book per Share Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.79 6.28 4.39 1.65 -1.71

Novavax Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 -1.06 -1.71 -2.17 -2.51

FRA:NVV1 vs MAZE, SLBT, AVLN: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Novavax's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novavax's Cyclically Adjusted PB Ratio falls into.


FRA:NVV1
49GF Score
Novavax Inc FRA:NVV1
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novavax's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-1.004/333.9520*333.9520
=-1.004

Current CPI (Jun. 2026) = 333.9520.

Novavax Quarterly Data

Book Value per Share CPI Adj_Book
201609 3.271 241.428 4.525
201612 -0.388 241.432 -0.537
201703 -1.925 243.801 -2.637
201706 -3.626 244.955 -4.943
201709 -4.011 246.819 -5.427
201712 -5.319 246.524 -7.205
201803 -4.648 249.554 -6.220
201806 -3.934 251.989 -5.214
201809 -5.673 252.439 -7.505
201812 -7.679 251.233 -10.207
201903 -5.677 254.202 -7.458
201906 -6.994 256.143 -9.119
201909 -6.752 256.759 -8.782
201912 -5.175 256.974 -6.725
202003 -0.403 258.115 -0.521
202006 2.677 257.797 3.468
202009 1.436 260.280 1.842
202012 7.266 260.474 9.316
202103 11.786 264.877 14.860
202106 8.334 271.696 10.244
202109 5.200 274.310 6.331
202112 -4.104 278.802 -4.916
202203 0.759 287.504 0.882
202206 -5.046 296.311 -5.687
202209 -7.284 296.808 -8.196
202212 -6.957 296.797 -7.828
202303 -9.694 301.836 -10.725
202306 -7.385 305.109 -8.083
202309 -5.353 307.789 -5.808
202312 -4.712 306.746 -5.130
202403 -5.683 312.332 -6.076
202406 -2.508 314.175 -2.666
202409 -2.962 315.301 -3.137
202412 -3.714 315.605 -3.930
202503 -0.432 319.799 -0.451
202506 0.201 322.561 0.208
202509 -0.822 324.800 -0.845
202512 -0.671 324.054 -0.691
202603 -0.762 330.213 -0.771
202606 -1.004 333.952 -1.004

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €-2.51 mean?
Novavax (FRA:NVV1) has a Cyclically Adjusted Book per Share of €-2.51 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novavax and its competitors.
Is Novavax's Cyclically Adjusted Book per Share too high?
Novavax's current Cyclically Adjusted Book per Share is €-2.51. Overall, Novavax has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Cyclically Adjusted Book per Share compare to MAZE and SLBT?
Novavax's Cyclically Adjusted Book per Share of €-2.51 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novavax and its competitors. Novavax's current Cyclically Adjusted Book per Share is €-2.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (FRA:NVV1) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.73, compared to a current price of €8.70 — trading 218.7% above its estimated fair value. The current Cyclically Adjusted Book per Share is €-2.51. Novavax's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Novavax (FRA:NVV1), the current Cyclically Adjusted Book per Share is €-2.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (FRA:NVV1) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of €8.70 is trading 218.7% above its estimated GF Value™ of €2.73. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for FRA:NVV1:

  • Cyclically Adjusted Book per Share: €-2.51
  • GF Value™: €2.73 vs. price of €8.70 (218.7% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the FRA:NVV1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
49GF Score

Get the complete analysis for FRA:NVV1

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.70
Price
€2.73
GF Value